Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Biotech, Univ of Miami Spin-Off Vaccine Company

Biotechnology company Heat Biologics Inc. is licensing research from University of Miami in Florida to develop vaccines against infectious diseases, starting with the Zika virus, in a new subsidiary. . . . → Read More: Biotech, Univ of Miami Spin-Off Vaccine Company

Refillable HIV Prevention Implant in Development

A device implanted under the skin providing 60 days of antiretroviral drugs to prevent HIV infection is in development at Houston Methodist Research Institute. . . . → Read More: Refillable HIV Prevention Implant in Development

Start-Up Licenses Genetics Technology for HIV Diagnostics

David Raiser, left, and Iain MacLeod, founders of Aldatu Biosciences (Aldatu Biosciences)

19 May 2016. A spin-off company from Harvard University is licensing genetics research to develop more powerful tools to detect drug-resistant strains of HIV. Financial details of the agreement between the 2 year-old Aldatu Biosciences Inc. and Harvard were not disclosed.

Aldatu . . . → Read More: Start-Up Licenses Genetics Technology for HIV Diagnostics

Gates Funding RNA Treatment for HIV Infection

RNA molecule illustration (Nicolle Rager Fuller, National Science Foundation)

12 January 2016. The Bill and Melinda Gates Foundation is backing a biotechnology company’s early development of antibodies to treat human immunodeficiency virus or HIV based on RNA, nucleic acids expressed by a person’s genetic code. The foundation is supporting the work of Moderna Therapeutics, . . . → Read More: Gates Funding RNA Treatment for HIV Infection

USC, Biotech Edit Genes in Stem Cells for HIV Therapy

Paula Cannon (University of Southern California)

10 November 2015. A lab at University of Southern California and biotechnology company developed a technique for editing genomes in blood-forming stem cells as a potential treatment for HIV infection. The team from the lab of USC medical school professor Paula Cannon and Sangamo BioSciences in Richmond, California . . . → Read More: USC, Biotech Edit Genes in Stem Cells for HIV Therapy

Research Group, CureVac Partner on AIDS Vaccine

(Rhoda Baer, National Cancer Institute)

10 September 2015. An organization encouraging development of AIDS vaccines and the pharmaceutical company CureVac are collaborating on creating a potent AIDS vaccine technology. Financial and intellectual property aspects of the partnership between the not-for-profit International AIDS Vaccine Initiative, or IAVI, and CureVac in Tubingen, Germany were not disclosed.

. . . → Read More: Research Group, CureVac Partner on AIDS Vaccine

Preventive Drugs Found to Stop New HIV Infections

Scanning electron micrograph of HIV particles infecting a human T cell (NIH.gov)

2 September 2015. A large-scale study of preexposure prophylaxis or PrEP, the use of antiviral drugs to prevent HIV infection, found the practice prevented new HIV infections among Kaiser Permanente clients in San Francisco over a 32-month period. Results of the study . . . → Read More: Preventive Drugs Found to Stop New HIV Infections

FDA Approves Pediatric HIV Drug Formulation

Scanning electron micrograph of HIV particles infecting a human T cell (NIH.gov)

5 June 2015. The U.S. Food and Drug Administration approved an application for a current HIV drug formulated to better treat infections in infants and young children, especially in limited resource regions. The formulation is a combination of lopinavir and ritonavir in . . . → Read More: FDA Approves Pediatric HIV Drug Formulation

GSK, UNC Chapel Hill Partner on HIV/AIDS Cure

Scanning electron micrograph of HIV particles infecting a human T cell (NIH.gov)

11 May 2015. Pharmaceutical maker GlaxoSmithKline and University of North Carolina in Chapel Hill are establishing a joint research center and spin-off company to develop new treatments for HIV and AIDS. GSK says it plans to invest $20 million over 5 years . . . → Read More: GSK, UNC Chapel Hill Partner on HIV/AIDS Cure

Biotech, Universities to Test Hydrogel for Vocal Fold Scars

(A. Kotok)

28 August 2014. BioTime Inc., a biotechnology company in Alameida, California, is partnering with researchers at University of Wisconsin and Université catholique de Louvain in Belgium to test its hydrogels for treating vocal cord scarring, a voice problem that results from injury or disease. Financial terms of the collaboration were not disclosed.

. . . → Read More: Biotech, Universities to Test Hydrogel for Vocal Fold Scars